Suppr超能文献

丝裂原活化蛋白激酶激酶激酶13-三结构域蛋白25-F盒蛋白7α轴影响c-Myc蛋白稳定性及肿瘤发展。

The MAP3K13-TRIM25-FBXW7α axis affects c-Myc protein stability and tumor development.

作者信息

Zhang Qiang, Li Xu, Cui Kasa, Liu Cheng, Wu Mingzhi, Prochownik Edward V, Li Youjun

机构信息

Hubei Key Laboratory of Cell Homeostasis, College of Life Sciences, Wuhan University, 430072, Wuhan, China.

Medical Research Institute, School of Medicine, Wuhan University, 430071, Wuhan, China.

出版信息

Cell Death Differ. 2020 Feb;27(2):420-433. doi: 10.1038/s41418-019-0363-0. Epub 2019 Jun 11.

Abstract

c-Myc (Myc) is a master transcription factor that is often deregulated and highly expressed by at least 50% of cancers. In many cases, Myc protein levels correlate with resistance to therapy and poor prognosis. However, effective direct inhibition of Myc by pharmacologic approaches has remained unachievable. Here, we identify MAP3K13 as a positive regulator of Myc to promote tumor development. Our findings show that MAP3K13 upregulation is predictive of poor outcomes in patients with hepatocellular carcinoma (HCC). Mechanistically, MAP3K13 phosphorylates the E3 ubiquitin ligase TRIM25 at Ser to decrease its polyubiquitination and proteasomal degradation. This newly stabilized TRIM25 then directly ubiquitinates Lys of FBXW7α, a core subunit of the SKP1-Cullin-F-box (SCF) ubiquitin ligase complex involved in Myc ubiquitination, thereby stabilizing Myc. Together, these results reveal a novel regulatory pathway that supervises Myc protein stability via the MAP3K13-TRIM25-FBXW7α signaling axis. In addition, they provide a potential therapeutic target in Myc over-expressing human cancers.

摘要

c-Myc(Myc)是一种主要的转录因子,在至少50%的癌症中经常失调并高表达。在许多情况下,Myc蛋白水平与治疗耐药性和不良预后相关。然而,通过药理学方法有效直接抑制Myc仍然无法实现。在此,我们确定丝裂原活化蛋白激酶激酶激酶13(MAP3K13)是Myc的一个正向调节因子,可促进肿瘤发展。我们的研究结果表明,MAP3K13上调可预测肝细胞癌(HCC)患者的不良预后。从机制上讲,MAP3K13在丝氨酸位点磷酸化E3泛素连接酶TRIM25,以减少其多聚泛素化和蛋白酶体降解。这种新稳定的TRIM25随后直接泛素化FBXW7α的赖氨酸,FBXW7α是参与Myc泛素化的SKP1- Culli n-F盒(SCF)泛素连接酶复合物的核心亚基,从而稳定Myc。总之,这些结果揭示了一条通过MAP3K13-TRIM25-FBXW7α信号轴监督Myc蛋白稳定性的新调控途径。此外,它们为Myc过表达的人类癌症提供了一个潜在的治疗靶点。

相似文献

1
The MAP3K13-TRIM25-FBXW7α axis affects c-Myc protein stability and tumor development.
Cell Death Differ. 2020 Feb;27(2):420-433. doi: 10.1038/s41418-019-0363-0. Epub 2019 Jun 11.
3
The F-box protein FBXL16 up-regulates the stability of C-MYC oncoprotein by antagonizing the activity of the F-box protein FBW7.
J Biol Chem. 2020 Jun 5;295(23):7970-7980. doi: 10.1074/jbc.RA120.012658. Epub 2020 Apr 28.
5
FBXL6 governs c-MYC to promote hepatocellular carcinoma through ubiquitination and stabilization of HSP90AA1.
Cell Commun Signal. 2020 Jun 23;18(1):100. doi: 10.1186/s12964-020-00604-y.
7
E3 ligase TRIM25 ubiquitinates RIP3 to inhibit TNF induced cell necrosis.
Cell Death Differ. 2021 Oct;28(10):2888-2899. doi: 10.1038/s41418-021-00790-3. Epub 2021 May 5.
8
Lysine-52 stabilizes the MYC oncoprotein through an SCF-independent mechanism.
Oncogene. 2017 Dec 7;36(49):6815-6822. doi: 10.1038/onc.2017.268. Epub 2017 Aug 14.
9
ELP3 stabilizes c-Myc to promote tumorigenesis.
J Mol Cell Biol. 2024 Apr 4;15(9). doi: 10.1093/jmcb/mjad059.
10
Fbxw7 acts as an E3 ubiquitin ligase that targets c-Myb for nemo-like kinase (NLK)-induced degradation.
J Biol Chem. 2008 Nov 7;283(45):30540-8. doi: 10.1074/jbc.M804340200. Epub 2008 Sep 2.

引用本文的文献

4
The FBXW7-RPAP2 Axis Controls the Growth of Hepatocellular Carcinoma Cells and Determines the Fate of Liver Cell Differentiation.
Adv Sci (Weinh). 2025 Apr;12(13):e2404718. doi: 10.1002/advs.202404718. Epub 2025 Feb 11.
5
Comparison of actionable alterations in cancers with kinase fusion, mutation, and copy number alteration.
PLoS One. 2025 Jan 23;20(1):e0305025. doi: 10.1371/journal.pone.0305025. eCollection 2025.
6
FBXW7 in gastrointestinal cancers: from molecular mechanisms to therapeutic prospects.
Front Pharmacol. 2024 Dec 18;15:1505027. doi: 10.3389/fphar.2024.1505027. eCollection 2024.
7
Targeting GOF p53 and c-MYC through LZK Inhibition or Degradation Suppresses Head and Neck Tumor Growth.
bioRxiv. 2024 Nov 20:2024.11.19.623840. doi: 10.1101/2024.11.19.623840.
8
Comparative transcriptomic analysis uncovers molecular heterogeneity in hepatobiliary cancers.
Transl Oncol. 2025 Jan;51:102192. doi: 10.1016/j.tranon.2024.102192. Epub 2024 Nov 14.
10
Molecular insights and clinical implications for the tumor suppressor role of SCF E3 ubiquitin ligase.
Biochim Biophys Acta Rev Cancer. 2024 Sep;1879(5):189140. doi: 10.1016/j.bbcan.2024.189140. Epub 2024 Jun 21.

本文引用的文献

1
PLK1: a promising and previously unexplored target in double-hit lymphoma.
J Clin Invest. 2018 Dec 3;128(12):5206-5208. doi: 10.1172/JCI124919. Epub 2018 Nov 5.
2
Mechanism of TRIM25 mediated ubiquitination of metastasis associated protein (MTA) 1 in normal liver cells.
Exp Cell Res. 2018 Oct 1;371(1):250-254. doi: 10.1016/j.yexcr.2018.08.018. Epub 2018 Aug 15.
4
Herpesvirus deconjugases inhibit the IFN response by promoting TRIM25 autoubiquitination and functional inactivation of the RIG-I signalosome.
PLoS Pathog. 2018 Jan 22;14(1):e1006852. doi: 10.1371/journal.ppat.1006852. eCollection 2018 Jan.
5
Survival of Head and Neck Cancer Cells Relies upon LZK Kinase-Mediated Stabilization of Mutant p53.
Cancer Res. 2017 Sep 15;77(18):4961-4972. doi: 10.1158/0008-5472.CAN-17-0267. Epub 2017 Jul 31.
7
Deubiquitinase USP13 maintains glioblastoma stem cells by antagonizing FBXL14-mediated Myc ubiquitination.
J Exp Med. 2017 Jan;214(1):245-267. doi: 10.1084/jem.20151673. Epub 2016 Dec 6.
8
PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression.
Nat Med. 2016 Nov;22(11):1321-1329. doi: 10.1038/nm.4213. Epub 2016 Oct 24.
9
microRNA-206 impairs c-Myc-driven cancer in a synthetic lethal manner by directly inhibiting MAP3K13.
Oncotarget. 2016 Mar 29;7(13):16409-19. doi: 10.18632/oncotarget.7653.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验